Relationship between IFN-γ gene polymorphism and susceptibility to intrauterine HBV infection

Table 1 Clinical characteristics of patients and controls

Subjects	n	Sex		HBV marker of mother		HBIg injection in pregnancy
		Male	Female	HBsAg+	HBsAg+ and HBeAg+	Yes	No
Group I	46	26	20	15	31	10	30
Group II	73	41	32	25	48	16	47
χ2		0.0015		0.0339		0.0020
P		0.9695		0.8539		0.9640

Group I: the intrauterine HBV infection group; Group II: the normal immune children group.

Table 2 Frequencies of IFN-γ+874 genotype in patients and controls

Subjects	n	Number of subjects and percentage ofIFN-γ+874 genotype (%)
		AA	AT	TT
Group I	46	31 (67.4)	9 (19.6)	6 (13.0)
Group II	73	33 (45.2)	22 (30.1)	18 (24.7)
χ2	5.102
P	0.02389

Group I: the intrauterine HBV infection group; Group II: the normal immune children group.

Table 3 +874T and +874A IFN-γ allele frequencies in patients and controls

	Allele(n)	IFN-γ+874A/T allelefrequencies (%)		OR(95% confidence interval)	χ2	P
		+874A	+874T
				3.228
Group I	46 (92)	71 (77.17)	21 (22.83)	(1.244-3.992)	7.238	0.0071
Group II	73 (146)	88 (60.27)	58 (39.73)

Group I: the intrauterine HBV infection group; Group II: the normal immune children group.

Table 4 IFN-γCA microsatellite morphisms in patients and controls

	n	Number and percentage of genotype of IFN-γCA (%)
		(CA12)+/(CA12)+	(CA12)+/(CA12)-	(CA12)-/(CA12)-
Group I	42	5 (11.90)	11 (26.19)	26 (61.91)
Group II	68	18 (26.47)	23 (33.82)	27 (39.71)
χ2	5.640
P	0.0176

Group I: the intrauterine HBV infection group; Group II: the normal immune children group.

Table 5 IFN-γ CA repeat times in patients and control

IFN-γ CArepeat	Group 1	Group II	χ2	P
	(84)	(136)
	% (n)	% (n)
11	1.19 (1)	0.74 (1)	0.119	0.7302
12	25 (21)	43.38 (59)	7.548	0.00601
13	13.10 (11)	8.82 (12)	1.008	0.3155
14	40.48 (34)	33.82 (46)	0.989	0.3201
15	13.10 (11)	7.35 (10)	1.974	0.1600
16	4.76 (4)	3.68 (5)	0.155	0.6936
17	2.38 (2)	2.21 (3)	0.007	0.9327

¹ Significant difference between patients and controls. Group I: the intrauterine HBV infection group; Group II: the normal immune children group.